Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection

NCT04818216 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.

NCT NCT04818216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04818216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection
Lead sponsor
The University of Texas Health Science Center at San Antonio
Phase
Phase 2
Overall status
Completed
Start date
June 11, 2021
Completion date
January 3, 2022
Enrollment
28 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, sars-cov-2 infection